Our proposed designs are motivated by a phase II trial of a lysyl oxidase homolog 2 (LOXL2) inhibitor, an MTA, in adult patients with primary, post polycythemia vera, or post essential thrombocythemia myelofibrosis. This evidence concerns the gene LOXL2 and myelofibrosis.